Document:

EX-4.3

 Exhibit 4.3 

Fiat Chrysler Automobiles N.V. (FCA or the Company) 

Remuneration Policy 

Remuneration Policy for Executive Directors 
 The Board of
Directors determines the compensation for our executive directors with reference to the remuneration policy. The policy is approved by shareholders. 
 The
objective of the remuneration policy is to provide a compensation structure that allows FCA to attract and retain the most highly qualified executive talent and by motivating them to achieve business and financial goals that create value for
shareholders in a manner consistent with our core business and leadership values. 
 Features of the remuneration for executive directors 

FCA’s compensation policy aims to provide total compensation that: 
  

	 	•	 	Attracts, retains and motivates qualified executives; 

  

	 	•	 	Is competitive against the comparable market; 

  

	 	•	 	Reinforces our performance driven culture and meritocracy; and 

  

	 	•	 	Is aligned to shareholders interests. 

 The remuneration structure for executive directors provides a fixed
component as well as short and long-term variable performance based components. FCA believes that the remuneration structure promotes the interests of FCA in the short and the long-term and is designed to encourage the executive directors to act in
the best interests of the Company and not in their own interests. In determining the level and structure of the compensation of the executive directors, the non-executive directors will take into account, among other things, the financial and
operational results as well as other business objectives of FCA. The Company establishes target compensation levels using a market-based approach and periodically benchmarks its executive compensation program against peer companies and monitors
compensation levels and trends in the market. 
 Fixed component 

The primary objective of the base salary (the fixed part of the annual cash compensation) for executive directors is to attract and retain well qualified
senior executives. The Company’s policy is to periodically benchmark comparable salaries paid to other executives with similar experience in its compensation peer group. 

Variable components 
 Executive directors are also
eligible to receive variable compensation subject to the achievement of pre-established financial and other designated performance targets. The variable components of executive directors’ remuneration, both the short and the long-term
components, are linked to predetermined, assessable targets. 

 Short-Term Incentives 

The primary objective of performance based short-term variable cash based incentives is to focus on the business priorities for the current or next year. The
executive directors’ variable incentive is based on achieving short-term (annual) financial and other designated objectives proposed by the Compensation Committee and approved by the non-executive directors each year. 

In regard to the executive directors’ annual performance bonus determination, the Compensation Committee and the non-executive directors: 

 

	 	•	 	approve the executive directors’ target and maximum allowable bonus, 

  

	 	•	 	select the choice and weighting of metrics, 

  

	 	•	 	set the stretch objectives, 

  

	 	•	 	review any unusual items that occurred in the performance year to determine the appropriate overall measurement of achievement, and 

  

	 	•	 	approve the final bonus determination. 

 In addition, upon proposal of the Compensation Committee, the
non-executive directors retain authority to grant periodic bonuses for specific transactions that are deemed exceptional in terms of strategic importance and effect on the Company’s results, with the form of any such bonus (cash, common shares
of the Company or options to purchase common shares) to be determined by the non-executive directors. 
 Long Term Incentives 

The primary objective of the performance based long-term variable equity based incentives is to reward and retain qualified executive directors over the longer
term while aligning their interests with those of shareholders. 
 FCA’s long-term variable incentives consist of a share-based incentive plan that
links a portion of the variable component to the achievement of pre-established performance targets consistent with the Company’s strategic horizon. As typical with the objective of using equity based awards, these awards help align the
executive directors’ interests with shareholder interests by delivering greater value to the executive director as shareholder value increases. 

Other Benefits 
 Executive directors may also be entitled
to usual and customary fringe benefits such as personal use of aircraft, company car and driver, personal/home security, medical insurance, accident insurance, tax preparation and financial counseling. The Compensation Committee may grant other
benefits to the executive directors in particular circumstances. 

  
 2 

 Remuneration Policy for Non-Executive Directors 

Remuneration of non-executive directors is approved by the Company’s shareholders and periodically reviewed by the Compensation Committee. The current
annual remuneration for the non-executive directors is: 
  

	 	•	 	$200,000 for each non-executive director 

  

	 	•	 	An additional $10,000 for each member of the Audit Committee and $20,000 for the Audit Committee Chairman 

  

	 	•	 	An additional $5,000 for each member of the Compensation Committee and the Governance Committee and $15,000 for the Compensation Committee Chairman and the Governance Committee Chairman 

 

	 	•	 	An additional $25,000 for the lead independent director 

  

	 	•	 	An automobile perquisite of one (1) assigned company-furnished vehicle, rotated semi-annually, subject to taxes related to imputed income/employee price on purchase or lease
of Company vehicles. 

 Non-executive directors elect whether their annual retainer fee will be made in half in cash and common shares of FCA
or 100% in common shares of FCA; whereas the committee membership and committee chair fee payments will be made all in cash (providing a Board fee structure common to other large multinational companies to help attract a multinational Board
membership). Remuneration of non-executive directors is fixed and not dependent on FCA’s financial results. Non-executive directors are not eligible for variable compensation and do not participate in any incentive plans. 

  
 3EX-4.2

 Exhibit 4.2 
  

 
 PARATEK PHARMACEUTICALS, INC. 
INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE 
COMMON STOCK COMMON STOCK 
PP CUSIP 699374 30 2 
is the owner of This Certifies that AUTHORIZED SIGNATURE TRANSFER AGENT
AND REGISTRAR 
(Brooklyn, NY) AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC

BY: COUNTERSIGNED AND REGISTERED: 
(the “Corporation”), a Delaware
corporation. The shares represented by this Certificate are transferable only on the stock transfer books of the 
Corporation by the holder of record hereof, or by
his duly authorized attorney or legal representative, upon the surrender of this Certificate properly 
endorsed. This Certificate is not valid until countersigned
and registered by the Corporation’s transfer agent and registrar. 
IN WITNESS WHEREOF, the Corporation has caused this Certificate to be executed by the
facsimile signatures of its duly authorized officers and 
has caused a facsimile of its corporate seal to be hereunto affixed. 
PARATEK PHARMACEUTICALS, INC. 
FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK, PAR VALUE
$0.001 PER SHARE OF 
SECRETARY CHAIRMAN AND CHIEF EXECUTIVE OFFICER 
Dated:

SECRETARY 
PARATEK PHARMACEUTICALS, INC 
Jan. 8, 2002 
CHAIRMAN AND CHIEF EXECUTIVE OFFICER 

 

 
 PARATEK PHARMACEUTICALS, INC. 
A statement of the
powers, designations, preferences and relative, participating, optional, or other special rights of each class of stock or series 
thereof and the qualifications,
limitations or restrictions of such preferences and/or rights as established, from time to time, by the Certificate of 
Incorporation of the Corporation and by any
certificate of designation, the number of shares constituting each class and series, and the 
designations thereof, may be obtained by the holder hereof upon
request and without charge at the principal office of the Corporation. 
The following abbreviations, when used in the inscription on the face of this certificate,
shall be construed as though they were written out in full 
according to applicable laws or regulations: 
TEN COM TEN ENTJT TEN UNIF GIFT MIN ACT — Custodian (Cust) (Minor) under Uniform Gifts to Minors 
Act (State) Additional abbreviations may also be used though not in the above list. 
PLEASE
INSERT SOCIAL SECURITY OR OTHER IDENTIFYING NUMBER OF ASSIGNEE 
(PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING ZIP CODE, OF ASSIGNEE) 
to transfer the said stock on the books of the within named Corporation with full power of substitution in the premises. of the capital stock represented by the within Certificate,
and dohereby irrevocably constitute and appoint 
shares Attorney 
THE SIGNATURE
TO THIS ASSIGNMENT MUST CORRESPOND WITH THE NAME AS WRITTEN UPON THE FACE OF THE CERTIFICATE IN EVERY PARTICULAR, WITHOUT ALTERATION OR ENLARGEMENT OR ANY CHANGE WHATEVER. NOTICE: SIGNATURE(S) GUARANTEED: 
THE SIGNATURE(S) MUST BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (BANKS, STOCKBROKERS, SAVINGS AND LOAN ASSOCIATIONS AND CREDIT UNIONS WITH MEMBERSHIP IN AN APPROVED
SIGNATURE GUARANTEE MEDALLION PROGRAM), PURSUANT TO S.E.C. RULE 17Ad-15. For value received, hereby sell, assign and transfer unto 
—as tenants in common

—as tenants by the entireties 
—as joint tenants with right of

survivorship and not as tenants 
in common 
Dated: 
This certificate also evidences and entitles the holder hereof to certain rights as set
forth in a Tax Benefit Preservation Plan between Paratek 
Pharmaceuticals, Inc. (f/k/a Transcept Pharmaceuticals, Inc.) (the “Company”) and American Stock
Transfer & Trust Company, LLC, as Rights 
Agent, dated as of September 13, 2013 as the same may be amended from time to time (the “Plan”), the terms
of which are hereby incorporated 
herein by reference and a copy of which is on file at the principal executive offices of the Company. Under certain circumstances,
as set forth 
in the Plan, such Rights (as defined in the Plan) will be evidenced by separate certificates and will no longer be evidenced by this certificate.

The Company will mail to the holder of this certificate a copy of the Plan without charge after receipt of a written request therefor. As described 
in the Plan, Rights which are owned by, transferred to or have been owned by Acquiring Persons (as defined in the Plan) or any 
Affiliate or Associate (as defined in the Plan) of any Acquiring Person shall become null and void and will no longer be transferable.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}]]